HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Activity of venetoclax-based therapy in chronic myelomonocytic leukemia.

AuthorsGuillermo Montalban-Bravo, Danielle Hammond, Courtney D DiNardo, Marina Konopleva, Gautam Borthakur, Nicholas J Short, Jorge Ramos-Perez, Veronica Guerra, Rashmi Kanagal-Shamanna, Kiran Naqvi, Koji Sasaki, Elias Jabbour, Naveen Pemmaraju, Tapan M Kadia, Farhad Ravandi, Naval Daver, Zeev Estrov, Sherry Pierce, Hagop Kantarjian, Guillermo Garcia-Manero
JournalLeukemia (Leukemia) Vol. 35 Issue 5 Pg. 1494-1499 (05 2021) ISSN: 1476-5551 [Electronic] England
PMID33846541 (Publication Type: Letter, Research Support, N.I.H., Extramural)
Chemical References
  • Antineoplastic Agents
  • Bridged Bicyclo Compounds, Heterocyclic
  • Sulfonamides
  • venetoclax
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents (therapeutic use)
  • Bridged Bicyclo Compounds, Heterocyclic (therapeutic use)
  • Female
  • High-Throughput Nucleotide Sequencing (methods)
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy, genetics)
  • Leukemia, Myelomonocytic, Chronic (drug therapy, genetics)
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes (drug therapy, genetics)
  • Sulfonamides (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: